Abstract: The present invention relates to a combination of an ERK1/2 inhibitor, 6,6-dimethyl-2-{2-[(1-methyl-1H-pyrazol-5-yl)amino]pyrimidin-4-yl}-5-[2-(morpholin-4-yl)ethyl]-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one, or a pharmaceutically acceptable salt thereof, with encorafenib, or a pharmaceutically acceptable salt thereof, and cetuximab and to methods of using these combinations to treat certain disorders, such as colorectal cancer.

Abstract: The present invention provides novel crystalline salt forms of 6,6-dimethyl-2-{2-[(1-methyl-1H-pyrazol-5-yl)amino]pyrimidin-4-yl}-5-[2-(morpholin-4-yl)ethyl]-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one.

Abstract: The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.

Abstract: The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.

Abstract: The present invention relates to novel aminopyridyloxypyrazole compounds that inhibit the activity of transforming growth factor beta receptor 1 (TGF?R1), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, preferably colon cancer, melanoma, hepatocellular carcinoma, renal cancer, glioblastoma, pancreatic cancer, myelodysplastic syndrome, lung cancer, and gastric cancer, and/or fibrosis, preferably liver fibrosis and chronic kidney disease.

Abstract: The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.

Abstract: The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.

Abstract: The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.

Abstract: The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.

Abstract: The present invention relates to novel aminopyridyloxypyrazole compounds that inhibit the activity of transforming growth factor beta receptor 1 (TGF?R1), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, preferably colon cancer, melanoma, hepatocellular carcinoma, renal cancer, glioblastoma, pancreatic cancer, myelodysplastic syndrome, lung cancer, and gastric cancer, and/or fibrosis, preferably liver fibrosis and chronic kidney disease.

Abstract: The present invention provides an aminopyrazole compound, or a pharmaceutically acceptable salt thereof, that inhibits Chk1 and is useful in the treatment of cancer.

Abstract: The present invention provides an aminopyrazole compound, or a pharmaceutically acceptable salt thereof, that inhibits Chk1 and is useful in the treatment of cancer.

Abstract: A turbine assembly, which may be part of a turbine generator assembly, includes a turbine flywheel assembly and a magnet motor within a turbine casing. The turbine flywheel assembly comprises a turbine flywheel rotatably coupled to a shaft, turbine blade assemblies mounted thereon and a magnet motor rotor assembly coupled to the shaft. The magnet motor rotor assembly includes rotor permanent magnets arranged in a ring around the shaft. The same pole of each includes rotor permanent magnet faces outward away from the shaft. A magnet motor stator assembly comprises stator magnet assemblies, each comprising a stator electromagnet and a stator permanent magnet, arranged in a ring around the magnet motor rotor assembly to exert replusive force on the nearest rotor permanent magnet. Selectably controllable nozzles inject compressed air onto the turbine blades. Electromagnet controller(s) individually and selectably activate, deactivate and polarity-switch the stator electromagnets.

Abstract: A turbine-generator system includes a power source powered by renewable energy. The power source drives a compressor, which outputs compressed air to pressurized tanks. A turbine is connected to the tanks via one or more nozzles. The turbine includes turbine blade assemblies and a turbine flywheel, each rotatably mounted to a shaft. The nozzles deliver compressed air to the turbine blades. The turbine includes a magnet motor for selectably applying torque to the turbine flywheel. The turbine is coupled to a generator via a magnetic clutch. An external control computer controls the rotational speed of the magnet motor and the amount and timing of the compressed air injected onto the turbine blades. A load sensor is coupled to an output of the generator and is in communication with the external control computer.

Abstract: An electricity generation system includes a generator, which comprises a rotor and a stator. Rotation of the rotor relative to the stator causes the generator to generate electricity. The rotational speed of the rotor is proportional to the power of the generated electricity. An excess power monitor is provided for determining when the power of the electricity generated by the generator exceeds a power demand. An energy regenerator is coupled to the excess power monitor. The excess power monitor diverts excess power to the energy regenerator when the power of the electricity generated by the generator exceeds the power demand. The energy regenerator converts the excess power into potential energy. The potential energy is stored in an energy storage coupled to the energy regenerator. The energy regenerator may be an air compressor and the energy storage may be one or more compressed air canister. Alternatively the energy regenerator may be a battery charger and the energy storage may be one or more battery.

Abstract: The present invention provides AKT and p70 S6 kinase inhibitors of the formula: The present invention also provides pharmaceutical compositions comprising compounds of Formula I, uses of compounds of Formula I and methods of using compounds of Formula I.

Abstract: The present invention provides p70 S6 kinase inhibitors of the formula: pharmaceutical formulations comprising them, and methods for their use.

Abstract: A clamp assembly comprising two brackets. Each bracket may include an elongated end, a curved section adjacent the elongated end, a channel formed by the curved section, and a mating surface adjacent the channel. When the mating surfaces of each bracket are in mating contact with each other, the channels of each bracket are substantially aligned with each other to form a shaft aperture. The brackets may be fitted together via a tongue and groove configuration and are coupled by way of mechanical fasteners at connection points on each bracket. Each bracket may comprise a coupling area that is configured to engage a mechanical fastener. The clamp assembly mounts to a shaft comprising a plurality of notched segments, wherein each notched segment has a cross-sectional shape that is substantially similar to the shaft aperture cross-sectional shape.

Abstract: The present invention provides p70 S6 kinase inhibitors of the formula: pharmaceutical formulations comprising them, and methods for their use.

Abstract: The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.